Tabula Rasa HealthCare (TRHC) 10-Q 2 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 15, 2017
Document and Entity Information
Entity Registrant Name	Tabula Rasa HealthCare, Inc.
Entity Central Index Key	1,651,561
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		17,218,168
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash	$ 2,805	$ 4,345
Accounts receivable, net	8,589	6,646
Inventories	3,021	2,911
Rebates receivable	315	312
Prepaid expenses	883	869
Other current assets	757	581
Total current assets	16,370	15,664
Property and equipment, net	6,889	6,409
Software development costs, net	3,762	3,350
Goodwill	21,686	21,686
Intangible assets, net	24,347	25,297
Other assets	323	333
Total assets	73,377	72,739
Current liabilities:
Current portion of long term debt	696	674
Acquisition-related consideration payable	579	568
Acquisition-related contingent consideration	1,531	1,493
Accounts payable	5,940	6,115
Accrued expenses and other liabilities	5,337	2,159
Total current liabilities	14,083	11,009
Long term debt	934	1,072
Long-term acquisition-related contingent consideration		1,515
Deferred income tax liability	927	832
Other long-term liabilities	2,307	2,205
Total liabilities	18,251	16,633
Commitments and contingencies (Note 16)
Stockholders' equity (deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2017 and December 31, 2016
Common stock, $0.0001 par value; 100,000,000 shares authorized, 17,097,080 and 16,628,476 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	2	2
Additional paid-in capital	92,928	91,027
Accumulated deficit	(37,804)	(34,923)
Total stockholders' equity	55,126	56,106
Total liabilities and stockholders' equity	$ 73,377	$ 72,739

CONSOLIDATED BALANCE SHEETS (pa

CONSOLIDATED BALANCE SHEETS (parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
CONSOLIDATED BALANCE SHEETS
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	17,097,080	16,628,476
Common stock, shares outstanding	17,097,080	16,628,476

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Product revenue	$ 22,696	$ 17,785
Service revenue	4,993	2,372
Total revenue	27,689	20,157
Cost of revenue, exclusive of depreciation and amortization shown below:
Product cost	17,405	12,982
Service cost	2,250	951
Total cost of revenue	19,655	13,933
Gross profit	8,034	6,224
Operating expenses:
Research and development	1,219	889
Sales and marketing	1,230	770
General and administrative	6,509	1,893
Change in fair value of acquisition-related contingent consideration	21	54
Depreciation and amortization	1,765	1,004
Total operating expenses	10,744	4,610
(Loss) income from operations	(2,710)	1,614
Other (income) expense:
Change in fair value of warrant liability		(134)
Interest expense	76	1,503
Total other expense	76	1,369
(Loss) income before income taxes	(2,786)	245
Income tax expense	95	36
Net (loss) income	(2,881)	209
Net (loss) income attributable to common stockholders:
Basic	(2,881)	293
Diluted	$ (2,881)	$ 94
Net (loss) income per share attributable to common stockholders:
Basic (in dollars per share)	$ (0.18)	$ 0.06
Diluted (in dollars per share)	$ (0.18)	$ 0.01
Weighted average common shares outstanding
Basic (in shares)	16,238,761	4,671,097
Diluted (in shares)	16,238,761	12,428,124

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - 3 months ended Mar. 31, 2017 - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at beginning of period at Dec. 31, 2016	$ 2	$ 91,027	$ (34,923)	$ 56,106
Balance at beginning of period (in shares) at Dec. 31, 2016	16,628,476
Increase (Decrease) in Stockholders' Equity
Issuance of restricted stock (in shares)	5,212
Shares surrendered by stockholder	(246)
Net exercise of stock options		(1,970)		(1,970)
Net exercise of stock options (in shares)	446,835
Exercise of stock options		50		50
Exercise of stock options (in shares)	16,803
Stock based compensation expense		3,821		3,821
Net (loss) income			(2,881)	(2,881)
Balance at end of period at Mar. 31, 2017	$ 2	$ 92,928	$ (37,804)	$ 55,126
Balance at end of period (in shares) at Mar. 31, 2017	17,097,080

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net (loss) income	$ (2,881)	$ 209
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	1,765	1,004
Amortization of deferred financing costs and debt discount	22	580
Payment of imputed interest on debt		(316)
Deferred taxes	95	22
Stock-based compensation	3,821	127
Change in fair value of warrant liability		(134)
Change in fair value of acquisition-related contingent consideration	21	54
Changes in operating assets and liabilities, net of effect from acquisitions:
Accounts receivable, net	(1,943)	175
Inventories	(110)	15
Rebates receivable	(3)	17
Prepaid expenses and other current assets	(207)	(162)
Other assets	(1)	(34)
Accounts payable		355
Accrued expenses and other liabilities	1,296	905
Other long-term liabilities	102	1,718
Net cash provided by operating activities	1,977	4,535
Cash flows from investing activities:
Purchases of property and equipment	(865)	(2,412)
Software development costs	(800)	(248)
Change in restricted cash		200
Net cash used in investing activities	(1,665)	(2,460)
Cash flows from financing activities:
Proceeds from exercise of stock options	50
Payments for employee taxes for shares withheld	(88)
Payments for debt financing costs	(18)
Borrowings on line of credit		2,000
Payments of acquisition-related consideration		(180)
Payments of initial public offering costs	(132)	(401)
Payments of contingent consideration	(1,498)	(1,895)
Repayments of long-term debt	(166)	(1,338)
Net cash used in financing activities	(1,852)	(1,814)
Net (decrease) increase in cash	(1,540)	261
Cash, beginning of period	4,345	2,026
Cash, end of period	2,805	2,287
Supplemental disclosure of cash flow information
Acquisition of equipment under capital leases	50	318
Additions to property, equipment, and software development purchases included in accounts payable	330	82
Deferred offering costs included in accounts payable		1,587
Cash paid for interest	51	771
Decretion of redeemable convertible preferred stock to redemption value		$ (403)
Employee payroll taxes on net exercise of stock options included in accrued expenses	$ 1,970

Nature of Business

Nature of Business	3 Months Ended
	Mar. 31, 2017
Nature of Business
Nature of Business	1. Nature of Business Tabula Rasa HealthCare, Inc. (the “Company”) provides patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The Company delivers its solutions through a comprehensive suite of technology-enabled products and services for medication risk management and risk adjustment. The Company serves healthcare organizations that focus on populations with complex healthcare needs and extensive medication requirements. The Company's suite of cloud-based software solutions provides prescribers, pharmacists and healthcare organizations with sophisticated and innovative tools to better manage the medication-related needs of patients. On October 4, 2016, the Company closed its initial public offering (the “IPO”) in which the Company issued and sold 4,300,000 shares of common stock, plus the exercise of the underwriters’ option to purchase an additional 645,000 shares of common stock, at an issuance price of $12.00 per share. The Company received net proceeds of $55,186 after deducting underwriting discounts and commissions of $4,154 but before deducting other offering expenses. In addition, upon the closing of the IPO, all of the Company’s then outstanding Class A Non-Voting common stock and Class B Voting common stock, totaling 5,583,405 shares, were automatically redesignated into shares of common stock, and all of the Company’s then outstanding convertible preferred stock converted into an aggregate of 5,089,436 shares of common stock. In addition, 202,061 shares of common stock were issued upon the automatic net exercise of outstanding warrants to purchase common stock that would have otherwise terminated immediately prior to the closing of the IPO. Additionally, in connection with the closing of the IPO, outstanding warrants to purchase shares of preferred stock converted into warrants to purchase an aggregate of 463,589 shares of common stock. Upon completion of the IPO on October 4, 2016, the Company filed an amended and restated certificate of incorporation to, among other things, state that the aggregate number of shares of stock that the Company is authorized to issue is 100,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.0001 per share.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company's significant accounting policies are disclosed in the Company’s audited consolidated financial statements for the year ended December 31, 2016, which are included in the Company’s annual report filed on Form 10-K on March 14, 2017 . Since the date of those audited consolidated financial statements, there have been no changes to the Company's significant accounting policies, including the status of recent accounting pronouncements, other than those detailed below. (a) Basis of Presentation The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments ( consisting of normal recurring accruals and adjustments) , necessary for the fair statement of the Company's interim consolidated financial position for the periods indicated. The interim results for the three months ended March 31, 2017 are not necessarily indicative of results to be expected for the year ending December 31, 2017, any other interim periods, or any future year or period. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s annual report as filed on Form 10-K. (b) Liquidity The Company's unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. Management believes that the Company's cash on hand of $2,805 as of March 31, 2017, cash flows from operations and borrowing availability under the Amended 2015 Revolving Line (Note 10) are sufficient to fund the Company's planned operations through at least June 30, 2018. (c) Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates or assumptions. (d) Revenue Recognition The Company recognizes revenue from product sales or services rendered when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered, (iii) the price to its client is fixed or determinable and (iv) collectability is reasonably assured. When the Company enters into arrangements with multiple deliverables, it applies the accounting guidance for revenue arrangements with multiple deliverables and evaluates each deliverable to determine whether it represents a separate unit of accounting based on the following criteria: (i) whether the delivered item has value to the customer on a standalone basis, and (ii) if the contract includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Revenue is allocated to each element in an arrangement based on a selling price hierarchy. The selling price for a deliverable is based on estimated selling prices ("ESP") as vendor specific objective evidence or third party evidence is not available. The Company establishes ESP for the elements of its arrangements based upon its pricing practices and class of customers. The stated prices for the various deliverables of the Company's contracts are consistent across classes of customers. Product Revenue The Company enters into multiple-element arrangements with healthcare organizations to provide software enabled medication risk management solutions. Under these contracts, revenue is generated through the components listed below. Prescription medication revenue The Company sells prescription medications directly to healthcare organizations through its prescription fulfillment pharmacies. Prescription medication fees are based upon the prices stated in customer contracts for the prescription and include a dispensing fee. Prescription medication revenue, including dispensing fees, is recognized when the product is shipped to the customer. Prescription medications are considered a separate unit of accounting. Per member per month fees — medication risk management services The Company receives a fixed monthly administrative fee for each member in the program contracted for medication risk management services. This fee, which is included in product revenue in the consolidated statement of operations, is recognized on a monthly basis as medication risk management services are provided. The services associated with the per member per month fees are considered a separate unit of accounting. Service Revenue The Company enters into contracts with healthcare organizations to provide (i) risk adjustment and (ii) pharmacy cost management services, which include training client staff and providers about documentation and diagnosis coding, analyzing clients' data collection and submission processes, and delivering meaningful analytics for understanding reimbursement complexities. In the third quarter of 2016, the Company began providing medication risk management services utilizing the Medication Risk Mitigation Matrix (“MRM Matrix”) technology alone, without the related fulfillment services, which are referred to as MRM Service Contracts. Under the risk adjustment contracts and MRM Service Contracts, there are generally three revenue generating components: Set up fees: The Company's contracts with its risk adjustment and MRM Service Contract customers often require customers to pay non-refundable set up fees, which are deferred and recognized over the estimated term of the contract. These fees are charged at the beginning of the customer relationship as compensation for the Company's efforts to prepare the customer and configure its system for the data collection process. The set up activities do not represent a separate unit of accounting as they do not have value apart from the broader risk adjustment and MRM Service Contracts. Incremental direct costs associated with such set up activities are also deferred and amortized over the shorter of the estimated customer life or stated contract period. Per member per month fees The Company receives a fixed monthly fee for each member in the respective programs. These services represent a separate unit of accounting and are offered independently from any other services. Revenue for these services is recognized each month as the services are performed. Hourly consulting fees The Company sometimes contracts with customers to perform various other services. Such services are billed on a time and materials basis, at agreed hourly rates. Consulting services represent a separate unit of accounting and are offered independently from any other services. Revenue for these services is recognized as time is incurred on the project. The Company's pharmacy cost management services include subscription revenue from customers and revenues from drug manufacturers for the sale of drug utilization data. Subscription revenue is recognized monthly as either a flat fee or as a percentage of monthly transactions incurred. Data and statistics fees from drug manufacturers are recognized as revenue when received due to the unpredictable nature of the payments and because fees are not fixed and determinable until received. (e) Cost of Product Revenue Cost of product revenue includes all costs directly related to the medication risk management offering, including costs relating to the Company's pharmacists' collaboration on a patient's medication management, clinical analysis of the results and, when necessary, offering guidance to the prescriber based upon the review of the medication risk mitigation matrix and the individual patient's medical history, as well as the fulfillment and distribution of prescription drugs. Costs consist primarily of the purchase price of the prescription drugs the Company dispenses, expenses to package, dispense and distribute prescription drugs, expenses associated with the Company's medication care plan support centers and prescription fulfillment centers, including employment costs and stock-based compensation, and expenses related to the hosting of the Company's technology platform. Such costs also include direct overhead expenses, as well as allocated miscellaneous overhead costs. The Company allocates miscellaneous overhead costs among functions based on employee headcount. (f) Cost of Service Revenue Cost of service revenue includes all labor costs, including stock-based compensation expense, directly related to the risk adjustment and pharmacy cost management services and expenses for claims processing, technology services and overhead costs. In addition, service costs include all costs directly related to servicing the Company’s MRM Service Contracts which primarily consist of labor costs, consultant fees, technology services and overhead costs. (g) R ecent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09") and has subsequently issued a number of amendments to ASU 2014-09. ASU 2014-09, as amended, represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to clients in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. ASU 2014-09 sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. For public companies, ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017 and interim reporting periods within that reporting period. Early adoption is permitted for annual reporting periods beginning after December 15, 2016; however, the Company does not intend to early adopt the new standard. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. The Company intends to adopt the new standard effective January 1, 2018 but has not yet determined which transition method will be used. The Company is currently analyzing significant contracts with customers to determine the impact of the adoption of ASU 2014-09 on the Company’s consolidated financial statements and disclosures. The Company will continue to assess all potential impacts of the standard on existing and new customer contracts during 2017, with a final evaluation of the impact of the adoption of the new standard expected to be completed by the end of 2017 . In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory ("ASU 2015-11"), which simplifies the subsequent measurement of inventories by replacing the current lower of cost or market test with a lower of cost and net realizable value test. ASU 2015-11 is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company has adopted ASU 2015-11 effective January 1, 2017. The adoption of this standard did not have any impact on the Company's consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"). The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the adoption of this standard and anticipates that this standard will have a material impact on the Company’s consolidated financial statements, as all long-term leases will be capitalized on the consolidated balance sheet. In March 2016, the FASB issued ASU 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"). The amendments in this update simplify certain aspects related to how share-based payments are accounted for and presented in the financial statements. The new guidance requires excess tax benefits and tax deficiencies be recorded as an income tax benefit or expense in the statement of operations when the awards vest or are settled and as operating cash flows when realized. The excess tax benefits are recognized regardless of the whether the benefit reduces income taxes payable in the current period. It also allows an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company adopted ASU 2016-09 effective January 1, 2017 and the adoption of this new standard did not have a material impact on the Company's consolidated financial statements in the first quarter of 2017. The Company elected to record forfeitures as they occur. There was no impact of this election because prior to the adoption, the Company’s historical forfeitures were de minimus. Excess tax benefits generated in the quarter ended March 31, 2017 totaled $6,287 and unrecognized tax benefits were $108 at December 31, 2016, however, there was no impact on the Company’s consolidated financial statements because of a full valuation allowance against deferred tax assets. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). ASU 2016-15 provides new guidance to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the potential impact of the adoption of ASU 2016-15 on the Company's consolidated financial statements. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (“ASU 2017-01”). ASU 2017-01 provides guidance for evaluating whether a set of transferred assets and activities (the “set”) should be accounted for as an acquisition of a business or group of assets. The guidance provides a screen to determine when a set does not qualify to be a business. When substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in an identifiable asset or a group of similar assets, the set is not a business. Also to be considered a business, the set would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. ASU 2017-01 is effective for financial statements issued for fiscal years beginning after December 15, 2017. The Company is currently evaluating the potential impact of the adoption of ASU 2017-01 on the Company's consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating the requirement to calculate the implied fair value of goodwill to measure an impairment charge. Instead, entities will be required to record an impairment charge based on the excess of a reporting unit’s carrying value over its fair value. ASU 2017-04 is effective for financial statements issued for fiscal years beginning after December 15, 2019. The Company is currently evaluating the potential impact of the adoption of ASU 2017-04 on the Company's consolidated financial statements.

Net (Loss) Income per Share

Net (Loss) Income per Share	3 Months Ended
	Mar. 31, 2017
Net Income (Loss) per Share
Net Income (Loss) per Share	3. Net (Loss) Income per Share Basic net (loss) income per share is computed by dividing net (loss) income attributable to common stockholders by the weighted average number of shares of common stock of the Company outstanding during the period. The Company computed net (loss) income per share of common stock using the treasury stock method for the three months ended March 31, 2017, and using the two-class method required for participating securities for the three months ended March 31, 2016. The Company considered its redeemable convertible preferred stock to be participating securities as the holders of the preferred stock were entitled to receive a dividend in the event that a dividend was paid on common stock. Diluted net (loss) income per share is computed by dividing net (loss) income attributable to common stockholders by the weighted average number of shares of common stock during the period plus the impact of dilutive securities, to the extent that they are not anti-dilutive. The following table presents the calculation of basic and diluted net (loss) income per share for the Company’s common stock : Three Months Ended March 31, 2017 2016 Numerator: Net (loss) income $ (2,881) $ 209 Decretion of redeemable convertible preferred stock — 403 Undistributed income attributable to redeemable convertible preferred stockholders — (319) Net (loss) income attributable to common stockholders, basic $ (2,881) $ 293 Decretion of redeemable convertible preferred stock — (403) Revaluation of warrant liability, net of tax — (115) Adjustment to undistributed income attributable to redeemable convertible preferred stockholders — 319 Net (loss) income attributable to common stockholders, diluted $ (2,881) $ 94 Denominator (basic): Weighted average shares of common stock outstanding, basic 16,238,761 4,671,097 Denominator (diluted): Weighted average shares of common stock outstanding 16,238,761 4,671,097 Effect of potential dilutive securities: Weighted average dilutive effect of stock options — 1,981,049 Weighted average dilutive effect of common shares from warrants — 361,206 Dilutive effect from preferred stock and preferred stock warrants assuming conversion — 5,414,772 Weighted average shares of common stock outstanding, diluted 16,238,761 12,428,124 Net (loss) income per share attributable to common stockholders, basic $ (0.18) $ 0.06 Net (loss) income per share attributable to common stockholders, diluted $ (0.18) $ 0.01 The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net (loss) income per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended March 31, 2017 2016 Stock options to purchase common stock 3,219,862 25,110 Restricted stock 727,858 — Common stock warrants 32,216 — 3,979,936 25,110 On October 4, 2016, the Company closed its IPO in which the Company issued and sold 4,300,000 shares of common stock, plus the exercise of the underwriters’ option to purchase an additional 645,000 shares, at an issuance price of $12.00 per share. See Notes 1 and 13 for additional information.

Acquisition

Acquisition	3 Months Ended
	Mar. 31, 2017
Acquisition
Acquisition	4. Acquisition On September 15, 2016, the Company acquired certain assets, consisting primarily of intellectual property and software assets of 9176-1916 Quebec Inc. (an entity indirectly controlled by our Chief Scientific Officer, Jacques Turgeon). The intellectual property and software assets were previously licensed by us and are integrated into the Company’s Medication Risk Mitigation Matrix. The purchase price consisted of cash consideration of up to $6,000, consisting of $1,000 which was paid upon closing, $4,400 paid during the fourth quarter of 2016, and $600 following the 12-month anniversary of the closing date of the acquisition, which is contingent upon no claims for indemnification being made pursuant to the purchase agreement. In addition to the cash consideration, the purchase price included an aggregate of $5,000 worth of common stock, which amounted to the issuance of 395,407 shares of common stock during the fourth quarter of 2016. The deferred acquisition cash consideration of $5,000 was recorded at its acquisition-date fair value of $4,955, using an assumed cost of debt of 7.8%. The $45 discount is being amortized to interest expense using the effective interest method through the consideration payment date. The Company amortized $11 of the discount to interest expense for the three months ended March 31, 2017. These amounts are included in acquisition-related consideration payable in the consolidated balance sheets as of March 31, 2017. As of March 31, 2017, the acquisition-related consideration balance was $579. The unaudited pro forma results presented below include the results of the 9176-1916 Quebec Inc. acquisition as if it had been consummated as of January 1, 2016. The unaudited pro forma results include the amortization associated with acquired intangible assets. Material nonrecurring charges directly attributable to the transactions are excluded. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2016. Three Months Ended March 31, 2016 Revenue $ 20,183 Net loss (144) Net loss per share attributable to common stockholders, basic (0.01) Net loss per share attributable to common stockholders, diluted (0.02)

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	5. Property and Equipment Depreciation and amortization expense on property and equipment for the three months ended March 31, 2017 and 2016 was $415 and $223, respectively.

Software Development Costs

Software Development Costs	3 Months Ended
	Mar. 31, 2017
Software Development Costs
Software Development Costs	6. Software Development Costs The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including external direct costs of material and services and payroll costs for employees directly involved with the software development. As of March 31, 2017 and December 31, 2016, gross capitalized software costs were $7,313 and $6,501 and accumulated amortization was $3,551 and $3,151, respectively. Amortization expense for the three months ended March 31, 2017 and 2016 was $400 and $205, respectively. As of March 31, 2017 and December 31, 2016, there was $1,590 and $911, respectively, of capitalized software costs that were not yet subject to amortization.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets
Goodwill and Intangible Assets	7. Goodwill and Intangible Assets The Company’s goodwill as of March 31, 2017 and December 31, 2016 was $21,686. Goodwill is not amortized, but instead tested for impairment annually. The Company conducted its annual impairment test as of October 1, 2016 and determined that there were no indicators of impairment during 2016. The next annual impairment test will be conducted as of October 1, 2017, unless the Company identifies a triggering event in the interim. Management has not identified any triggering events during the three months ended March 31, 2017. Intangible assets consisted of the following as of March 31, 2017 and December 31, 2016: Weighted Average Amortization Period Accumulated Intangible (in years) Gross Value Amortization Assets, net March 31, 2017 Trade names 5.00 $ 1,940 $ (890) $ 1,050 Client relationships 10.02 14,684 (3,659) 11,025 Non-competition agreements 4.64 652 (360) 292 Developed technology 7.76 13,500 (1,547) 11,953 Domain name 10.00 29 (2) 27 Total intangible assets $ 30,805 $ (6,458) $ 24,347 Weighted Average Amortization Period Accumulated Intangible (in years) Gross Value Amortization Assets, net December 31, 2016 Trade names 5.00 $ 1,940 $ (791) $ 1,149 Client relationships 10.02 14,684 (3,289) 11,395 Non-competition agreements 4.64 652 (326) 326 Developed technology 7.76 13,500 (1,101) 12,399 Domain name 10.00 29 (1) 28 Total intangible assets $ 30,805 $ (5,508) $ 25,297 Amortization expense for intangible assets for the three months ended March 31, 2017 and 2016 was $950 and $576, respectively. The estimated amortization expense for each of the next five years and thereafter is as follows: Years Ending December 31, 2017 (April 1 - December 31) $ 2,842 2018 3,755 2019 3,649 2020 3,309 2021 3,169 Thereafter 7,623 $ 24,347

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	3 Months Ended
	Mar. 31, 2017
Accrued Liabilities and Other Liabilities
Accrued Expenses and Other Liabilities	8. Accrued Expenses and Other Liabilities At March 31, 2017 and December 31, 2016, accrued expenses and other liabilities consisted of the following: March 31, 2017 December 31, 2016 Employee related expenses $ 4,320 $ 1,174 Deferred revenue 751 851 Interest 19 16 Deferred rent 18 13 Other expenses 229 105 Total accrued expenses and other liabilities $ 5,337 $ 2,159 Accrued employee related expenses as of March 31, 2017 includes $1,970 of accrued payroll taxes that the Company will remit to taxing authorities on behalf of certain employees for shares withheld from the net exercise of stock options during the first quarter of 2017.

Notes Payable Related to Acquis

Notes Payable Related to Acquisition	3 Months Ended
	Mar. 31, 2017
Notes Payable Related to Acquisition
Notes Payable Related to Acquisition	9. Notes Payable Related to Acquisition In December 2014, the Company acquired all of the authorized, issued and outstanding equity interests of Medliance LLC ("Medliance"), which provides pharmacy cost management services through data analytics. As part of the acquisition-related consideration of the Medliance acquisition, the Company issued multiple subordinated convertible promissory notes (the "Medliance Notes") to the owners of Medliance for aggregate borrowings of $16,385. Interest was 8% and compounded annually. On July 1, 2016, the Company repaid the Medliance Notes with the proceeds from a long-term credit facility. Interest expense was $353 for the three months ended March 31, 2016. The Company recorded the Medliance Notes at their aggregate acquisition date fair values of $14,347 and the notes were accreted up to their face values of $16,385 over the 18 month term using the effective-interest method. For the three months ended March 31, 2016, the Company amortized $363 of the discount to interest expense.

Lines of Credit and Long-Term D

Lines of Credit and Long-Term Debt	3 Months Ended
	Mar. 31, 2017
Lines of Credit and Long-Term Debt
Lines of Credit and Long-Term Debt	10. Lines of Credit and Long-Term Debt (a) Lines of Credit On July 1, 2016, the Company entered into a Loan and Security Modification Agreement (the "Amended 2015 Revolving Line") with Western Alliance Bank, successor in interest to Bridge Bank, National Association (“Bridge Bank”), whereby the Company’s revolving line of credit, entered into with Bridge Bank in 2015 was amended to increase the Company's borrowing availability to up to $25,000 and extend the maturity date to July 1, 2018. The Company's ability to borrow under the Amended 2015 Revolving Line is based upon a specified borrowing base equal to the Company's trailing four months of monthly recurring revenue, as defined, from eligible recurring revenue contracts, as defined, through March 31, 2017 and based upon the Company's trailing three months of monthly recurring revenue, as defined, from eligible recurring revenue contracts, as defined, thereafter. Interest on the Amended 2015 Revolving Line was also amended to be calculated at a variable rate based upon Western Alliance Bank's prime rate plus 0.5%, with Western Alliance Bank's prime rate having a floor of 3.5%. Financial covenants under the Amended 2015 Revolving Line require that the Company (i) maintain an unrestricted cash and unused availability balance under the Amended 2015 Revolving Line of at least $3,000 at all times (the liquidity covenant), (ii) maintain a minimum EBITDA, as defined, of $2,500 for the quarter ending December 31, 2016 and thereafter, and (iii) maintain a minimum monthly recurring revenue retention rate of at least 90%, measured quarterly. As of March 31, 2017, the Company was in compliance with all of the financial covenants related to the Amended 2015 Revolving Line, and management expects that the Company will be able to maintain compliance with the financial covenants. In September 2015, the Company arranged for Bridge Bank to issue a $500 letter of credit on its behalf in connection with the Company’s lease agreement for the office space in Moorestown, NJ (see Note 16). The letter of credit renews annually and expires in September 2027 and reduces amounts available on the line of credit. As of March 31, 2017, there were no aggregate borrowings outstanding under the Amended 2015 Revolving Line, and amounts available for borrowings under the Amended 2015 Revolving Line was $24,500. As of March 31, 2017, the interest rate on the Amended 2015 Revolving Line was 4.56% and no interest expense was incurred for the three months ended March 31, 2017 as there were no aggregate borrowings outstanding during the three months ended March 31, 2017. As of March 31, 2016, the interest rate on the Amended 2015 Revolving Line was 4.56% and interest expense was $133 for the three months ended March 31, 2016. In connection with the 2015 Revolving Line and the Amended 2015 Revolving Line, the Company recorded deferred financing costs of $159. The Company is amortizing the deferred financing costs to interest expense using the effective-interest method over the term of the Amended 2015 Revolving Line and amortized $11 and $13 to interest expense for the three months ended March 31, 2017 and 2016, respectively. (b) Capital Lease Obligations The following table represents the total capital lease obligations of the Company at March 31, 2017 and December 31, 2016: March 31, 2017 December 31, 2016 Capital leases $ 1,630 $ 1,746 Less current portion, net (696) (674) Total capital leases, less current portion, net $ 934 $ 1,072 The Company has entered into leases for certain equipment and software, which are recorded as capital lease obligations. These leases have interest rates ranging from 7% to 22%. Interest expense related to the capital leases was $57 and $43 for the three months ended March 31, 2017 and 2016, respectively. Amortization of assets held under capital leases is included in depreciation and amortization expense. The net book value of equipment and software acquired under capital lease was $2,190 and $2,364 as of March 31, 2017 and December 31, 2016, respectively, and are reflected in property and equipment on the consolidated balance sheets. (c) Long-Term Debt Maturities As of March 31, 2017, the Company's long-term debt consisted of capital lease obligations and is payable as follows: Total long-term debt Remainder of 2017 $ 665 2018 779 2019 439 2020 31 2021 4 1,918 Less amount representing interest (288) Present value of payments 1,630 Less current portion (696) Total long-term debt, net of current portion $ 934 (d) Other Financing In May 2016, the Company signed a prime vendor agreement with AmerisourceBergen Drug Corporation, which was effective March 2016 and requires a monthly minimum purchase obligation of approximately $1,750. The Company fully expects to meet this requirement. This agreement was subsequently amended and restated effective May 1, 2016 with a three-year term expiring April 2019. As of March 31, 2017 and December 31, 2016, the Company had $3,686 and $3,327, respectively, due to AmerisourceBergen Drug Corporation as a result of prescription drug purchases. Pursuant to the terms of a security agreement entered into in connection with the prime vendor agreement, AmerisourceBergen also holds a subordinated security interest in all of the Company’s assets.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Taxes
Income Taxes	11. Income Taxes For the three months ended March 31, 2017, the Company recorded income tax expense of $95 related to indefinite-lived deferred tax liabilities for goodwill amortization, which resulted in an effective tax rate of (3.4)% for the period. The Company has recorded a full valuation allowance against its deferred tax assets as of March 31, 2017 and December 31, 2016. Accordingly, the year to date tax benefit was limited to the amount of the benefit that can be recognized for the full year, and the Company used the actual effective tax rate for the year to date as its best estimate to determine the Company’s tax expense for the three months ended March 31, 2017. For the three months ended March 31, 2016, the Company recognized tax expense of $36, which resulted in an effective tax rate of 14.7%. For the three months ended March 31, 2016, the Company calculated the tax provision based on its estimated annual effective tax rate expected for the full year which included current Federal alternative minimum tax, current state taxes and deferred tax expense associated with indefinite-lived deferred tax liabilities for goodwill amortization, in addition to a change in the valuation allowance related to deferred tax assets for income generated in the current period.

Other Long-term Liabilities

Other Long-term Liabilities	3 Months Ended
	Mar. 31, 2017
Other Long-term Liabilities
Other Long-term Liabilities	12. Other Long-term Liabilities Other long term liabilities as of March 31, 2017 consisted of $2,307, which represents the long-term portion of deferred rent primarily related to the Company's operating leases for office space in Moorestown, NJ.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2017
Stockholders' Equity
Stockholders' Equity	13. Stockholders' Equity (a) Capitalization and Initial Public Offering On October 4, 2016, the Company closed its IPO in which the Company issued and sold 4,300,000 shares of common stock, plus the exercise of the underwriters’ option to purchase an additional 645,000 shares of common stock, at an issuance price of $12.00 per share. The Company received net proceeds of $55,186 after deducting underwriting discounts and commissions of $4,154 but before deducting other offering expenses. In addition, upon the closing of the IPO, all of the Company’s then outstanding Class A Non-Voting common stock and Class B Voting common stock, totaling 5,583,405 shares, were automatically redesignated into shares of common stock, and all of the Company’s then outstanding convertible preferred stock converted into an aggregate of 5,089,436 shares of common stock. Upon completion of the IPO on October 4, 2016, the Company filed an amended and restated certificate of incorporation to, among other things, state that the aggregate number of shares of stock that the Company is authorized to issue is 100,000,000 shares of common stock, par value $.0001 per share, and 10,000,000 shares of undesignated preferred stock, par value $.0001 per share. (b) Common Stock Warrants As of March 31, 2017, warrants to purchase 32,216 shares of common stock were outstanding. These warrants have an exercise price of $1.55 and expire in October 2022. On April 7, 2017, 28,431 shares of common stock were issued upon the net exercise of these warrants in full. During the three months ended March 31, 2016, the Company issued 210,817 shares of common stock upon the net exercise of warrants to purchase 232,787 shares of common stock.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2017
Stock-Based Compensation
Stock-Based Compensation	14. Stock-Based Compensation In September 2016, the Company adopted the 2016 Equity Compensation Plan (the “2016 Plan”) and merged the 2014 Equity Compensation Plan (the “2014 Plan”) into the 2016 Plan on September 28, 2016. No additional grants were made thereafter under the 2014 Plan. Outstanding grants under the 2014 Plan will continue in effect according to their terms as in effect before the merger with the 2016 Plan, and the shares with respect to outstanding grants under the 2014 Equity Plan will be issued or transferred under the 2016 Plan. The 2016 Plan authorizes the issuance or transfer of up to the sum of the following: (1) 800,000 new shares, plus (2) the number of shares of common stock subject to outstanding grants under the 2014 Equity Plan as of the effective date of the 2016 Plan; provided, however, that the aggregate number of shares of the Company’s common stock that may be issued or transferred under the 2016 Plan pursuant to incentive stock options may not exceed 800,000. During the term of the 2016 Plan, the share reserve will automatically increase on the first trading day in January of each calendar year, beginning in calendar year 2017, by an amount equal to the lesser of 5% of the total number of outstanding shares of common stock on the last trading day in December of the prior calendar year or such other number set by the Company’s Board of Directors (the “Board”). During 2017, the Board approved an increase of 831,423 shares to the share reserve. As of March 31, 2017, 498,429 shares were available for future grants under the 2016 Plan. The option price per share cannot be less than the fair market value of a share on the date the option was granted, and in the case of incentive stock options granted to an employee owning more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall not be less than 110% of the fair market value of Company stock on the date of grant. Stock option grants under the Plan generally expire 10 years from the date of grant, other than incentive stock option grants to 10% shareholders, which have a 5 year term, 90 days after termination, or one year after the date of death or termination due to disability. Stock options generally vest over a period of four years, with 25% of the options becoming exercisable on the one-year anniversary of the commencement date and the remaining shares vesting monthly thereafter for 36 months in equal installments of 2.08% per month. On September 28, 2016, the Board granted 700,386 shares of restricted common stock to certain Company employees, including executive officers, under the 2014 Plan, prior to merging it with the 2016 Plan, pursuant to a special equity award pool previously approved by the Board which was made immediately prior to the effectiveness of the Company's registration statement filed in connection with the Company's IPO. All shares of restricted common stock will vest in full on May 31, 2017. The value of the grants is based on the IPO price of $12.00 per share and the related non-cash compensation expense is being recognized ratably over the vesting period from the date of grant through May 31, 2017, when the shares underlying the grant fully vest. For the three months ended March 31, 2017, $3,075 of expense was recognized related to this grant. As of March 31, 2017, there was unrecognized compensation expense of $2,084 related to this grant. On September 28, 2016, the Company granted 22,260 shares of restricted common stock under the 2016 Plan to our non-employee directors, which represents both the initial and annual grants to such directors. The initial grant will vest in three substantially equal annual installments over three years following the grant date and the annual grant will vest in full on the earlier of the next annual shareholder meeting or the one year anniversary of the grant date. The value of the grants is based on the IPO price of $12.00. On March 8, 2017, the Company granted 5,212 shares of restricted common stock under the 2016 Plan to a newly appointed non-employee director, which represents such director’s initial grant and will vest in three substantially equal annual installments over three years following the grant date. The value of the grant is based on the grant date fair value of the Company’s common stock of $13.68. For the three months ended March 31, 2017, $56 of expense was recognized related to these grants. As of March 31, 2017, there was unrecognized compensation expense of $244 related to these grants. The Company recorded $690 and $127 of stock-based compensation expense related to the vesting of employee and non-employee stock options for the three months ended March 31, 2017 and 2016, respectively. The estimated fair value of options granted was calculated using a Black- Scholes option-pricing model. The computation of expected life for employees was determined based on the simplified method. The risk-free rate is based on the U.S. Treasury security with terms equal to the expected time of exercise as of the grant date. The Company's common stock had not been publicly traded until the IPO commenced on September 29, 2016; therefore, expected volatility is based on the historical volatilities of selected public companies whose services are comparable to that of the Company. The table below sets forth the weighted average assumptions for employee grants during the three months ended March 31, 2017 and 2016: Three Months Ended March 31, Valuation assumptions: 2017 2016 Expected volatility 61.00 % 59.00 % Expected term (years) 6.03 6.08 Risk-free interest rate 2.24 % 1.49 % Dividend yield — — The weighted average grant date fair value of employee options granted during the three months ended March 31, 2017 and 2016 was $7.89 and $7.29, respectively. The following table summarizes stock option activity under the 2016 Plan for the three months ended March 31, 2017: Weighted Weighted average average remaining Aggregate Number exercise contractual intrinsic of shares price term value Outstanding at December 31, 2016 3,059,690 $ 5.14 Granted 961,075 14.03 Exercised (793,225) 3.61 Forfeited (7,678) 11.31 Outstanding at March 31, 2017 3,219,862 $ 8.16 7.7 $ 18,186 Options vested and expected to vest at March 31, 2017 3,219,862 $ 8.16 7.7 $ 18,186 Exercisable at March 31, 2017 1,535,362 $ 3.02 5.6 $ 16,065 Included within the above table are 188,893 non-employee options outstanding as of March 31, 2017, of which 1,241 are unvested as of March 31, 2017 and therefore subject to remeasurement. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the Company’s closing stock price or estimated fair value on the last trading day of the fiscal quarter for those stock options that had exercise prices lower than the fair value of the Company's common stock. This amount changes based on the fair market value of the Company’s stock. The total intrinsic value of options exercised during the three months ended March 31, 2017 and 2016 was $8,660 and $832, respectively. As of March 31, 2017, there was $11,096 of total unrecognized compensation cost related to nonvested stock options granted under the 2016 Plan, which is expected to be recognized over a weighted average period of 3.1 years. Cash received from option exercises for the three months ended March 31, 2017 was $50. During 2017, 329,587 shares of common stock were delivered by option holders as payment for the exercise price and employee payroll taxes owed for the exercise of 776,422 stock options with a gross exercise value of $2,816. During 2016, 7,930 shares of common stock were delivered by option holders as payment for the exercise of 71,150 stock options with a gross exercise value of $104. No cash was received from the exercise of stock options for the three months ended March 31, 2016. The Company recorded total stock-based compensation expense for the three months ended March 31, 2017 and 2016, in the following expense categories of its consolidated statement of operations: Three Months Ended March 31, 2017 2016 Cost of revenue - product $ 95 $ 29 Cost of revenue - service 43 7 Research and development 104 11 Sales and marketing 117 22 General and administrative 3,462 58 $ 3,821 $ 127

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2017
Fair Value Measurements
Fair Value Measurements	15. Fair Value Measurements The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses, acquisition-related consideration payable, acquisition-related contingent consideration, and long-term debt. The carrying values of accounts receivable, accounts payable and accrued expenses are representative of their fair value due to the relatively short-term nature of those instruments. The carrying value of the Company’s long-term debt approximates fair value based on the terms of the debt. The Company has classified liabilities measured at fair value on a recurring basis at March 31, 2017 and December 31, 2016 as follows: Fair Value Measurement at Reporting Date Using Balance as of Level 1 Level 2 Level 3 March 31, 2017 Liabilities Acquisition-related contingent consideration - short-term — — 1,531 1,531 $ — $ — $ 1,531 $ 1,531 Fair Value Measurement at Reporting Date Using Balance as of Level 1 Level 2 Level 3 December 31, 2016 Liabilities Acquisition-related contingent consideration - short-term $ — $ — $ 1,493 $ 1,493 Acquisition-related contingent consideration - long-term — — 1,515 1,515 $ — $ — $ 3,008 $ 3,008 Acquisition-related contingent consideration is measured at fair value on a recurring basis using unobservable inputs, hence these instruments represent Level 3 measurements within the fair value hierarchy. The acquisition-related contingent consideration liability represents the estimated fair value of the additional cash consideration payable that is contingent upon the achievement of certain financial and performance milestones. The changes in fair value of the Company’s acquisition-related contingent consideration for the three months ended March 31, 2017 was as follows: Balance at December 31, 2016 3,008 Fair value of cash consideration paid (1,498) Adjustments to fair value measurement 21 Balance at March 31, 2017 $ 1,531

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies
Commitments and Contingencies	16. Commitments and Contingencies The Company is not currently involved in any significant claims or legal actions that, in the opinion of management, will have a material adverse impact on the Company. As of March 31, 2017 and December 31, 2016, the Company was contingently liable for $500 under an outstanding letter of credit related to the Company’s lease agreement for the office space in Moorestown, NJ (see Note 10).

Retirement Plan

Retirement Plan	3 Months Ended
	Mar. 31, 2017
Retirement Plan
Retirement Plan	17. Retirement Plan The Company has established a 401(k) plan that qualifies as a defined contribution plan under Section 401 of the Internal Revenue Code. The Company’s contributions to this plan are based on a percentage of eligible employees’ plan year earnings, as defined. The Company made contributions to participants’ accounts totaling $136 during the three months ended March 31, 2017. The Company did not make any contributions to participants’ accounts during the three months ended March 31, 2016.

Related-Party Transactions

Related-Party Transactions	3 Months Ended
	Mar. 31, 2017
Related-Party Transactions
Related-Party Transactions	18. Related-Party Transactions During 2016, there was a demand promissory note with a stockholder with a balance outstanding of $250, which bears interest at 6% annually. The demand promissory note was repaid in full in October 2016 with the proceeds from the IPO. Total interest expense from these related-party borrowings was $4 for the three months ended March 31, 2016.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events
Subsequent Events	19. Subsequent Events On April 25, 2017, the Company entered into employment agreements with each of the Company’s named executive officers . The employment agreements provide for, among other things, salary, incentive compensation, payments in the event of termination upon the occurrence of a change in control, and restrictive covenants pursuant to which the executives have agreed to refrain from competing with the Company or soliciting the Company’s employees or customers for a period following the executive’s termination of employment. Each employment agreement is effective as of April 1, 2017, has an initial three year term and will automatically renew each anniversary thereafter. On April 25, 2017, the Company’s Board also adopted the Annual Incentive Plan, effective as of January 1, 2017, which formalizes the Company’s annual short-term incentive program and does not represent a new compensation program for the named executive officers. The Plan provides pay for performance incentive compensation to the Company’s employees, including its named executive officers, rewarding them for their contributions to the Company with cash incentive compensation based on attainment of pre-determined corporate and individual performance goals, as applicable. On April 25, 2017 the Board authorized the Company to repurchase up to $5,000 of its common stock. The Company expects to fund repurchases of its common stock through a combination of cash on hand, cash generated by operations and borrowings under its line of credit. As of the date of this filing the Company has not repurchased any shares pursuant this authorization.

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Summary of Significant Accounting Policies
Basis of Presentation	(a) Basis of Presentation The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments ( consisting of normal recurring accruals and adjustments) , necessary for the fair statement of the Company's interim consolidated financial position for the periods indicated. The interim results for the three months ended March 31, 2017 are not necessarily indicative of results to be expected for the year ending December 31, 2017, any other interim periods, or any future year or period. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s annual report as filed on Form 10-K.
Liquidity	(b) Liquidity The Company's unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. Management believes that the Company's cash on hand of $2,805 as of March 31, 2017, cash flows from operations and borrowing availability under the Amended 2015 Revolving Line (Note 10) are sufficient to fund the Company's planned operations through at least June 30, 2018.
Use of Estimates	(c) Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates or assumptions.
Revenue Recognition	(d) Revenue Recognition The Company recognizes revenue from product sales or services rendered when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered, (iii) the price to its client is fixed or determinable and (iv) collectability is reasonably assured. When the Company enters into arrangements with multiple deliverables, it applies the accounting guidance for revenue arrangements with multiple deliverables and evaluates each deliverable to determine whether it represents a separate unit of accounting based on the following criteria: (i) whether the delivered item has value to the customer on a standalone basis, and (ii) if the contract includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Revenue is allocated to each element in an arrangement based on a selling price hierarchy. The selling price for a deliverable is based on estimated selling prices ("ESP") as vendor specific objective evidence or third party evidence is not available. The Company establishes ESP for the elements of its arrangements based upon its pricing practices and class of customers. The stated prices for the various deliverables of the Company's contracts are consistent across classes of customers. Product Revenue The Company enters into multiple-element arrangements with healthcare organizations to provide software enabled medication risk management solutions. Under these contracts, revenue is generated through the components listed below. Prescription medication revenue The Company sells prescription medications directly to healthcare organizations through its prescription fulfillment pharmacies. Prescription medication fees are based upon the prices stated in customer contracts for the prescription and include a dispensing fee. Prescription medication revenue, including dispensing fees, is recognized when the product is shipped to the customer. Prescription medications are considered a separate unit of accounting. Per member per month fees — medication risk management services The Company receives a fixed monthly administrative fee for each member in the program contracted for medication risk management services. This fee, which is included in product revenue in the consolidated statement of operations, is recognized on a monthly basis as medication risk management services are provided. The services associated with the per member per month fees are considered a separate unit of accounting. Service Revenue The Company enters into contracts with healthcare organizations to provide (i) risk adjustment and (ii) pharmacy cost management services, which include training client staff and providers about documentation and diagnosis coding, analyzing clients' data collection and submission processes, and delivering meaningful analytics for understanding reimbursement complexities. In the third quarter of 2016, the Company began providing medication risk management services utilizing the Medication Risk Mitigation Matrix (“MRM Matrix”) technology alone, without the related fulfillment services, which are referred to as MRM Service Contracts. Under the risk adjustment contracts and MRM Service Contracts, there are generally three revenue generating components: Set up fees: The Company's contracts with its risk adjustment and MRM Service Contract customers often require customers to pay non-refundable set up fees, which are deferred and recognized over the estimated term of the contract. These fees are charged at the beginning of the customer relationship as compensation for the Company's efforts to prepare the customer and configure its system for the data collection process. The set up activities do not represent a separate unit of accounting as they do not have value apart from the broader risk adjustment and MRM Service Contracts. Incremental direct costs associated with such set up activities are also deferred and amortized over the shorter of the estimated customer life or stated contract period. Per member per month fees The Company receives a fixed monthly fee for each member in the respective programs. These services represent a separate unit of accounting and are offered independently from any other services. Revenue for these services is recognized each month as the services are performed. Hourly consulting fees The Company sometimes contracts with customers to perform various other services. Such services are billed on a time and materials basis, at agreed hourly rates. Consulting services represent a separate unit of accounting and are offered independently from any other services. Revenue for these services is recognized as time is incurred on the project. The Company's pharmacy cost management services include subscription revenue from customers and revenues from drug manufacturers for the sale of drug utilization data. Subscription revenue is recognized monthly as either a flat fee or as a percentage of monthly transactions incurred. Data and statistics fees from drug manufacturers are recognized as revenue when received due to the unpredictable nature of the payments and because fees are not fixed and determinable until received.
Cost of Product Revenue	(e) Cost of Product Revenue Cost of product revenue includes all costs directly related to the medication risk management offering, including costs relating to the Company's pharmacists' collaboration on a patient's medication management, clinical analysis of the results and, when necessary, offering guidance to the prescriber based upon the review of the medication risk mitigation matrix and the individual patient's medical history, as well as the fulfillment and distribution of prescription drugs. Costs consist primarily of the purchase price of the prescription drugs the Company dispenses, expenses to package, dispense and distribute prescription drugs, expenses associated with the Company's medication care plan support centers and prescription fulfillment centers, including employment costs and stock-based compensation, and expenses related to the hosting of the Company's technology platform. Such costs also include direct overhead expenses, as well as allocated miscellaneous overhead costs. The Company allocates miscellaneous overhead costs among functions based on employee headcount.
Cost of Service Revenue	(f) Cost of Service Revenue Cost of service revenue includes all labor costs, including stock-based compensation expense, directly related to the risk adjustment and pharmacy cost management services and expenses for claims processing, technology services and overhead costs. In addition, service costs include all costs directly related to servicing the Company’s MRM Service Contracts which primarily consist of labor costs, consultant fees, technology services and overhead costs.
Recent Accounting Pronouncements	(g) R ecent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09") and has subsequently issued a number of amendments to ASU 2014-09. ASU 2014-09, as amended, represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to clients in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services. ASU 2014-09 sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. For public companies, ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017 and interim reporting periods within that reporting period. Early adoption is permitted for annual reporting periods beginning after December 15, 2016; however, the Company does not intend to early adopt the new standard. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. The Company intends to adopt the new standard effective January 1, 2018 but has not yet determined which transition method will be used. The Company is currently analyzing significant contracts with customers to determine the impact of the adoption of ASU 2014-09 on the Company’s consolidated financial statements and disclosures. The Company will continue to assess all potential impacts of the standard on existing and new customer contracts during 2017, with a final evaluation of the impact of the adoption of the new standard expected to be completed by the end of 2017 . In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory ("ASU 2015-11"), which simplifies the subsequent measurement of inventories by replacing the current lower of cost or market test with a lower of cost and net realizable value test. ASU 2015-11 is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company has adopted ASU 2015-11 effective January 1, 2017. The adoption of this standard did not have any impact on the Company's consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"). The new standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the adoption of this standard and anticipates that this standard will have a material impact on the Company’s consolidated financial statements, as all long-term leases will be capitalized on the consolidated balance sheet. In March 2016, the FASB issued ASU 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"). The amendments in this update simplify certain aspects related to how share-based payments are accounted for and presented in the financial statements. The new guidance requires excess tax benefits and tax deficiencies be recorded as an income tax benefit or expense in the statement of operations when the awards vest or are settled and as operating cash flows when realized. The excess tax benefits are recognized regardless of the whether the benefit reduces income taxes payable in the current period. It also allows an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company adopted ASU 2016-09 effective January 1, 2017 and the adoption of this new standard did not have a material impact on the Company's consolidated financial statements in the first quarter of 2017. The Company elected to record forfeitures as they occur. There was no impact of this election because prior to the adoption, the Company’s historical forfeitures were de minimus. Excess tax benefits generated in the quarter ended March 31, 2017 totaled $6,287 and unrecognized tax benefits were $108 at December 31, 2016, however, there was no impact on the Company’s consolidated financial statements because of a full valuation allowance against deferred tax assets. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). ASU 2016-15 provides new guidance to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the potential impact of the adoption of ASU 2016-15 on the Company's consolidated financial statements. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (“ASU 2017-01”). ASU 2017-01 provides guidance for evaluating whether a set of transferred assets and activities (the “set”) should be accounted for as an acquisition of a business or group of assets. The guidance provides a screen to determine when a set does not qualify to be a business. When substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in an identifiable asset or a group of similar assets, the set is not a business. Also to be considered a business, the set would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. ASU 2017-01 is effective for financial statements issued for fiscal years beginning after December 15, 2017. The Company is currently evaluating the potential impact of the adoption of ASU 2017-01 on the Company's consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating the requirement to calculate the implied fair value of goodwill to measure an impairment charge. Instead, entities will be required to record an impairment charge based on the excess of a reporting unit’s carrying value over its fair value. ASU 2017-04 is effective for financial statements issued for fiscal years beginning after December 15, 2019. The Company is currently evaluating the potential impact of the adoption of ASU 2017-04 on the Company's consolidated financial statements.

Net (Loss) Income per Share (Ta

Net (Loss) Income per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Net Income (Loss) per Share
Schedule of calculation of basic and diluted net loss per share	Three Months Ended March 31, 2017 2016 Numerator: Net (loss) income $ (2,881) $ 209 Decretion of redeemable convertible preferred stock — 403 Undistributed income attributable to redeemable convertible preferred stockholders — (319) Net (loss) income attributable to common stockholders, basic $ (2,881) $ 293 Decretion of redeemable convertible preferred stock — (403) Revaluation of warrant liability, net of tax — (115) Adjustment to undistributed income attributable to redeemable convertible preferred stockholders — 319 Net (loss) income attributable to common stockholders, diluted $ (2,881) $ 94 Denominator (basic): Weighted average shares of common stock outstanding, basic 16,238,761 4,671,097 Denominator (diluted): Weighted average shares of common stock outstanding 16,238,761 4,671,097 Effect of potential dilutive securities: Weighted average dilutive effect of stock options — 1,981,049 Weighted average dilutive effect of common shares from warrants — 361,206 Dilutive effect from preferred stock and preferred stock warrants assuming conversion — 5,414,772 Weighted average shares of common stock outstanding, diluted 16,238,761 12,428,124 Net (loss) income per share attributable to common stockholders, basic $ (0.18) $ 0.06 Net (loss) income per share attributable to common stockholders, diluted $ (0.18) $ 0.01
Schedule of shares excluded from the calculation of diluted net loss per share attributable to common stockholders	Three Months Ended March 31, 2017 2016 Stock options to purchase common stock 3,219,862 25,110 Restricted stock 727,858 — Common stock warrants 32,216 — 3,979,936 25,110

Acquisition (Tables)

Acquisition (Tables)	3 Months Ended
	Mar. 31, 2017
Acquisition
Schedule of proforma results	Three Months Ended March 31, 2016 Revenue $ 20,183 Net loss (144) Net loss per share attributable to common stockholders, basic (0.01) Net loss per share attributable to common stockholders, diluted (0.02)

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets
Schedule of intangible assets	Weighted Average Amortization Period Accumulated Intangible (in years) Gross Value Amortization Assets, net March 31, 2017 Trade names 5.00 $ 1,940 $ (890) $ 1,050 Client relationships 10.02 14,684 (3,659) 11,025 Non-competition agreements 4.64 652 (360) 292 Developed technology 7.76 13,500 (1,547) 11,953 Domain name 10.00 29 (2) 27 Total intangible assets $ 30,805 $ (6,458) $ 24,347 Weighted Average Amortization Period Accumulated Intangible (in years) Gross Value Amortization Assets, net December 31, 2016 Trade names 5.00 $ 1,940 $ (791) $ 1,149 Client relationships 10.02 14,684 (3,289) 11,395 Non-competition agreements 4.64 652 (326) 326 Developed technology 7.76 13,500 (1,101) 12,399 Domain name 10.00 29 (1) 28 Total intangible assets $ 30,805 $ (5,508) $ 25,297
Schedule of estimated amortization expense	Years Ending December 31, 2017 (April 1 - December 31) $ 2,842 2018 3,755 2019 3,649 2020 3,309 2021 3,169 Thereafter 7,623 $ 24,347

Accrued Expenses and Other Li30

Accrued Expenses and Other Liabilities (Tables)	3 Months Ended
	Mar. 31, 2017
Accrued Liabilities and Other Liabilities
Schedule of accrued expenses and other liabilities	March 31, 2017 December 31, 2016 Employee related expenses $ 4,320 $ 1,174 Deferred revenue 751 851 Interest 19 16 Deferred rent 18 13 Other expenses 229 105 Total accrued expenses and other liabilities $ 5,337 $ 2,159

Lines of Credit and Long-Term31

Lines of Credit and Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2017
Lines of Credit and Long-Term Debt
Schedule of capital lease obligations	March 31, 2017 December 31, 2016 Capital leases $ 1,630 $ 1,746 Less current portion, net (696) (674) Total capital leases, less current portion, net $ 934 $ 1,072
Schedule of maturities of long-term debt payable	Total long-term debt Remainder of 2017 $ 665 2018 779 2019 439 2020 31 2021 4 1,918 Less amount representing interest (288) Present value of payments 1,630 Less current portion (696) Total long-term debt, net of current portion $ 934

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2017
Stock-Based Compensation
Schedule of weighted average assumptions for employee grants	Three Months Ended March 31, Valuation assumptions: 2017 2016 Expected volatility 61.00 % 59.00 % Expected term (years) 6.03 6.08 Risk-free interest rate 2.24 % 1.49 % Dividend yield — —
Summary of stock option activity	Weighted Weighted average average remaining Aggregate Number exercise contractual intrinsic of shares price term value Outstanding at December 31, 2016 3,059,690 $ 5.14 Granted 961,075 14.03 Exercised (793,225) 3.61 Forfeited (7,678) 11.31 Outstanding at March 31, 2017 3,219,862 $ 8.16 7.7 $ 18,186 Options vested and expected to vest at March 31, 2017 3,219,862 $ 8.16 7.7 $ 18,186 Exercisable at March 31, 2017 1,535,362 $ 3.02 5.6 $ 16,065
Schedule of recorded stock-based compensation expense related to stock options	Three Months Ended March 31, 2017 2016 Cost of revenue - product $ 95 $ 29 Cost of revenue - service 43 7 Research and development 104 11 Sales and marketing 117 22 General and administrative 3,462 58 $ 3,821 $ 127

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2017
Change in fair value
Schedule of classified liabilities measured at fair value on recurring basis	Fair Value Measurement at Reporting Date Using Balance as of Level 1 Level 2 Level 3 March 31, 2017 Liabilities Acquisition-related contingent consideration - short-term — — 1,531 1,531 $ — $ — $ 1,531 $ 1,531 Fair Value Measurement at Reporting Date Using Balance as of Level 1 Level 2 Level 3 December 31, 2016 Liabilities Acquisition-related contingent consideration - short-term $ — $ — $ 1,493 $ 1,493 Acquisition-related contingent consideration - long-term — — 1,515 1,515 $ — $ — $ 3,008 $ 3,008
Acquisition related contingent consideration
Change in fair value
Schedule of reconciliation of liability measured at fair value on recurring basis using significant unobservable inputs (Level 3)	Balance at December 31, 2016 3,008 Fair value of cash consideration paid (1,498) Adjustments to fair value measurement 21 Balance at March 31, 2017 $ 1,531

Nature of Business (Details)

Nature of Business (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 07, 2017	Oct. 04, 2016	Mar. 31, 2016	Mar. 31, 2017	Dec. 31, 2016
Initial Public Offering
Common stock authorized shares		100,000,000		100,000,000	100,000,000
Shares of common stock, par value (in dollars per share)		$ 0.0001		$ 0.0001	$ 0.0001
Shares of undesignated preferred stock, authorized		10,000,000		10,000,000	10,000,000
Shares of undesignated preferred stock, par value (in dollars per share)		$ 0.0001		$ 0.0001	$ 0.0001
Common stock warrants
Initial Public Offering
Shares issued upon exercise of warrants (in shares)	28,431		210,817
Number of shares issuable upon net exercise of outstanding warrants		463,589	232,787
Common Stock
Initial Public Offering
Redesignation of Class A and Class B common stock upon initial public offering (in shares)		5,583,405
Conversion of redeemable convertible preferred stock upon initial public offering (in shares)		5,089,436
Shares issued upon exercise of warrants (in shares)		202,061
IPO
Initial Public Offering
Issuance of common stock upon public offering (in shares)		4,300,000
Issuance price (in dollars per share)		$ 12
Proceeds from issuance of common stock under initial public offering, net of underwriting costs		$ 55,186
Underwriting discounts and commissions		$ 4,154
Underwriter option
Initial Public Offering
Issuance of common stock upon public offering (in shares)		645,000

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Liquidity, Revenue and AR (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)item	Dec. 31, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Summary of Significant Accounting Policies
Cash on hand | $	$ 2,805	$ 4,345	$ 2,287	$ 2,026
Substantial doubt about going concern, within one year	false
Revenue Recognition
Number of revenue generating components | item	3

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Recent Accounting Pronouncements
Unrecognized tax benefits			$ 108
Income tax expense	$ 95	$ 36
Accounting Standards Update 2016-09 | Adjustment
Recent Accounting Pronouncements
Excess tax benefits offset with valuation allowance	6,287
Income tax expense	$ 0

Net (Loss) Income per Share - E

Net (Loss) Income per Share - EPS (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Numerator
Net (loss) income	$ (2,881)	$ 209
Decretion of redeemable convertible preferred stock		403
Undistributed income attributable to redeemable convertible preferred stockholders		(319)
Net (loss) income attributable to common stockholders, basic	(2,881)	293
Decretion of redeemable convertible preferred stock		(403)
Revaluation of warrant liability		(115)
Adjustment to undistributed income attributable to redeemable convertible preferred stockholders		319
Net (loss) income attributable to common stockholders, diluted	$ (2,881)	$ 94
Denominator (basic):
Weighted average shares of common stock outstanding, basic	16,238,761	4,671,097
Denominator (diluted):
Weighted average shares of common stock outstanding, basic	16,238,761	4,671,097
Effect of potential dilutive securities:
Weighted average dilutive effect of stock options		1,981,049
Weighted average dilutive effect of common shares from warrants		361,206
Dilutive effect from preferred stock and preferred stock warrants assuming conversion		5,414,772
Weighted average shares of common stock outstanding, diluted	16,238,761	12,428,124
Net (loss) income per share attributable to common stockholders, basic (in dollars per share)	$ (0.18)	$ 0.06
Net (loss) income per share attributable to common stockholders, diluted (in dollars per share)	$ (0.18)	$ 0.01

Net (Loss) Income per Share - A

Net (Loss) Income per Share - Anti-dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	3,979,936	25,110
Employee stock options
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	3,219,862	25,110
Restricted stock
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	727,858
Common stock warrants
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	32,216

Net (Loss) Income per Share - I

Net (Loss) Income per Share - IPO (Details)	Oct. 04, 2016$ / sharesshares
IPO
Initial Public Offering
Issuance of common stock upon public offering (in shares)	4,300,000
Issuance price (in dollars per share) | $ / shares	$ 12
Underwriter option
Initial Public Offering
Issuance of common stock upon public offering (in shares)	645,000

Acquisitions - Quebec Inc (Deta

Acquisitions - Quebec Inc (Details) - USD ($) $ in Thousands	Sep. 15, 2017	Sep. 15, 2016	Mar. 31, 2017	Dec. 31, 2016
Acquisition
Acquisition-related consideration payable			$ 579	$ 568
Quebec Inc.
Acquisition
Cash consideration, high end of range		$ 6,000
Cash consideration		1,000		$ 4,400
Deferred stock consideration		5,000
Equity consideration (in shares)				395,407
Deferred acquisition cash consideration		5,000
Acquisition-date fair value of deferred cash consideration		$ 4,955
Cost of debt (as a percent)		7.80%
Discount		$ 45
Amortization of discount			11
Acquisition-related consideration payable			$ 579
Quebec Inc. | Plan
Acquisition
Cash consideration	$ 600

Acquisitions - Pro forma (Detai

Acquisitions - Pro forma (Details) - Quebec Inc. $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)$ / shares
Acquisition
Revenue | $	$ 20,183
Net loss | $	$ (144)
Net loss per share attributable to common stockholders, basic (in dollars per share) | $ / shares	$ (0.01)
Net loss per share attributable to common stockholders, diluted (in dollars per share) | $ / shares	$ (0.02)

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Property and Equipment
Depreciation and amortization expense	$ 1,765	$ 1,004
Property and equipment
Property and Equipment
Depreciation and amortization expense	$ 415	$ 223

Software Development Costs (Det

Software Development Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Software Development Costs
Gross capitalized software costs	$ 7,313		$ 6,501
Accumulated amortization	3,551		3,151
Amortization expense	400	$ 205
Capitalized software costs not yet subject to amortization	$ 1,590		$ 911

Goodwill and Intangible Asset44

Goodwill and Intangible Assets - Goodwill (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Goodwill and related changes
Goodwill	$ 21,686	$ 21,686

Goodwill and Intangible Asset45

Goodwill and Intangible Assets - Intangible assets (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Intangible Assets
Gross Value	$ 30,805		$ 30,805
Accumulated Amortization	(6,458)		(5,508)
Intangible Assets, net	24,347		$ 25,297
Amortization expense	$ 950	$ 576
Trade names
Intangible Assets
Weighted Average Amortization Period	5 years		5 years
Gross Value	$ 1,940		$ 1,940
Accumulated Amortization	(890)		(791)
Intangible Assets, net	$ 1,050		$ 1,149
Client relationships
Intangible Assets
Weighted Average Amortization Period	10 years 7 days		10 years 7 days
Gross Value	$ 14,684		$ 14,684
Accumulated Amortization	(3,659)		(3,289)
Intangible Assets, net	$ 11,025		$ 11,395
Non-competition agreements
Intangible Assets
Weighted Average Amortization Period	4 years 7 months 21 days		4 years 7 months 21 days
Gross Value	$ 652		$ 652
Accumulated Amortization	(360)		(326)
Intangible Assets, net	$ 292		$ 326
Developed technology
Intangible Assets
Weighted Average Amortization Period	7 years 9 months 4 days		7 years 9 months 4 days
Gross Value	$ 13,500		$ 13,500
Accumulated Amortization	(1,547)		(1,101)
Intangible Assets, net	$ 11,953		$ 12,399
Domain name
Intangible Assets
Weighted Average Amortization Period	10 years		10 years
Gross Value	$ 29		$ 29
Accumulated Amortization	(2)		(1)
Intangible Assets, net	$ 27		$ 28

Goodwill and Intangible Asset46

Goodwill and Intangible Assets - Amortization (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Estimated amortization expense
2,017	$ 2,842
2,018	3,755
2,019	3,649
2,020	3,309
2,021	3,169
Thereafter	7,623
Estimated amortization expense	$ 24,347	$ 25,297

Accrued Expenses and Other Li47

Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Accrued Liabilities and Other Liabilities
Employee related expenses	$ 4,320	$ 1,174
Deferred revenue	751	851
Interest	19	16
Deferred rent	18	13
Other expenses	229	105
Total accrued expenses and other liabilities	5,337	$ 2,159
Employee payroll taxes on net exercise of stock options included in accrued expenses	$ 1,970

Notes Payable Related to Acqu48

Notes Payable Related to Acquisition (Details) - Medliance - Subordinated convertible promissory notes - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Dec. 31, 2014	Mar. 31, 2016
Notes Payable Related to Acquisition
Aggregate borrowings	$ 16,385
Interest rate (as a percent)	8.00%
Interest expense recognized		$ 353
Fair value of promissory notes	$ 14,347
Term of debt	18 months
Amortization of discount to interest expense		$ 363

Lines of Credit and Long-Term49

Lines of Credit and Long-Term Debt - Lines of Credit (Details) - 2015 Revolving Line - USD ($) $ in Thousands	Jul. 01, 2016	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Sep. 30, 2015
Lines of Credit
Maximum borrowing capacity	$ 25,000
Number of months of monthly recurring revenue through March 31, 2017	4 months
Number of months of monthly recurring revenue thereafter	3 months
Minimum unrestricted cash and unused availability balance required	$ 3,000
Minimum EBITDA			$ 2,500
Minimum monthly recurring revenue retention rate (as a percent)	90.00%
Letter of credit liability		$ 500	$ 500		$ 500
Aggregate borrowings outstanding		0
Amounts available for borrowings		$ 24,500
Interest rate (as a percent)		4.56%		4.56%
Interest expense		$ 0		$ 133
Deferred financing costs	$ 159
Amortization of deferred financing costs to interest expense		$ 11		$ 13
Prime Rate
Lines of Credit
Spread on variable rate (as a percent)	0.50%
Floor rate (as a percent)	3.50%

Lines of Credit and Long-Term50

Lines of Credit and Long-Term Debt - Capital Lease Obligations (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Capital Lease Obligations
Capital leases	$ 1,630	$ 1,746
Less current portion, net	(696)	(674)
Total long-term debt/capital leases, net of current portion	$ 934	$ 1,072

Lines of Credit and Long-Term51

Lines of Credit and Long-Term Debt - Capital Leases (Details) - Capital Lease Obligation - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Capital Lease Obligations
Interest expense, capital lease	$ 57	$ 43
Net book value of assets under capital leases	$ 2,190		$ 2,364
Minimum
Capital Lease Obligations
Lease interest rates (as a percent)	7.00%
Maximum
Capital Lease Obligations
Lease interest rates (as a percent)	22.00%

Lines of Credit and Long-Term52

Lines of Credit and Long-Term Debt - Debt Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Capital lease obligations
Remainder of 2017	$ 665
2,018	779
2,019	439
2,020	31
2,021	4
Total	1,918
Less amount representing interest	(288)
Present value of payments	1,630
Less current portion, net	(696)	$ (674)
Total long-term debt/capital leases, net of current portion	$ 934	$ 1,072

Lines of Credit and Long-Term53

Lines of Credit and Long-Term Debt - Other Financing (Details) - AmerisourceBergen Drug Corporation - USD ($) $ in Thousands	1 Months Ended
	May 31, 2016	Mar. 31, 2017	Dec. 31, 2016
Other Financing
Monthly minimum purchase obligation	$ 1,750
Purchase obligation, period	3 years
Amount due as a result of prescription drug purchases		$ 3,686	$ 3,327

Income Taxes - Expense (Details

Income Taxes - Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Taxes
Income tax expense	$ 95	$ 36
Effective tax rate (as a percent)	(3.40%)	14.70%

Other Long-term Liabilities (De

Other Long-term Liabilities (Details) $ in Thousands	Mar. 31, 2017USD ($)
Other Long-term Liabilities.
Other Long-term Liabilities
Long-term portion of deferred rent	$ 2,307

Stockholders' Equity - Capitali

Stockholders' Equity - Capitalization and IPO (Details) - USD ($) $ / shares in Units, $ in Thousands	Oct. 04, 2016	Mar. 31, 2017	Dec. 31, 2016
Capitalization and Initial Public Offering
Common stock authorized shares	100,000,000	100,000,000	100,000,000
Shares of common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Shares of undesignated preferred stock, authorized	10,000,000	10,000,000	10,000,000
Shares of undesignated preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
IPO
Capitalization and Initial Public Offering
Issuance of common stock upon public offering, net of issuance costs (in shares)	4,300,000
Issuance price (in dollars per share)	$ 12
Proceeds from issuance of common stock under initial public offering, net of underwriting costs	$ 55,186
Underwriting discounts and commissions	$ 4,154
Underwriter option
Capitalization and Initial Public Offering
Issuance of common stock upon public offering, net of issuance costs (in shares)	645,000
Common Stock
Capitalization and Initial Public Offering
Redesignation of Class A and Class B common stock upon initial public offering (in shares)	5,583,405
Conversion of redeemable convertible preferred stock upon initial public offering (in shares)	5,089,436

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock Warrants (Details) - Common stock warrants - $ / shares	Apr. 07, 2017	Mar. 31, 2016	Mar. 31, 2017	Oct. 04, 2016
Warrants
Number of warrants outstanding			32,216
Exercise Price (in dollars per share)			$ 1.55
Shares issued upon exercise of warrants (in shares)	28,431	210,817
Number of shares called by warrant issued		232,787		463,589

Stock-Based Compensation - Plan

Stock-Based Compensation - Plans (Details) - shares	Sep. 28, 2016	Mar. 31, 2017	Mar. 31, 2017
Stock options
Stock-Based Compensation
Expiration term		10 years
Vesting period		4 years
Stock options | Vesting, Tranche 1
Stock-Based Compensation
Vesting period		1 year
Vesting (as a percent)		25.00%
Stock options | Vesting, Tranche 2
Stock-Based Compensation
Period of monthly vesting		36 months
Monthly vesting (as a percent)		2.08%
Stock options | Employee owning more than 10% of voting power
Stock-Based Compensation
Expiration term		5 years
Expiration term after termination		90 days
Expiration term after death or termination due to disability		1 year
Stock options | Minimum | Employee owning more than 10% of voting power
Stock-Based Compensation
Ownership (as a percent)		10.00%	10.00%
Option price as percentage of fair market value of common stock on the date of grant		110.00%
2014 Plan | Restricted stock
Stock-Based Compensation
Awards, other than options, granted (in shares)			0
2014 Plan | Stock options
Stock-Based Compensation
Options granted (in shares)			0
2016 Plan
Stock-Based Compensation
Options granted (in shares)		961,075
Threshold limit to issue or transfer authorized shares (in shares)	800,000
Automatic increase on share reserve (as a percent)	5.00%
Additional shares authorized		831,423
Available for future grant (in shares)		498,429	498,429

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted stock (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 08, 2017	Sep. 28, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017
Stock-Based Compensation
Stock-based compensation expense (in dollars)			$ 3,821	$ 127
2014 Plan | Restricted stock
Stock-Based Compensation
Awards, other than options, granted (in shares)					0
2014 Plan | Restricted stock | Award Date of September 28, 2016
Stock-Based Compensation
Awards, other than options, granted (in shares)		700,386
Share price (in dollars per share)		$ 12
Stock-based compensation expense (in dollars)			3,075
Unrecognized compensation expense (in dollars)			2,084		$ 2,084
2016 Plan | Restricted stock | Award Date of September 28, 2016
Stock-Based Compensation
Awards, other than options, granted (in shares)		22,260
Share price (in dollars per share)		$ 12
Stock-based compensation expense (in dollars)			56
Unrecognized compensation expense (in dollars)			$ 244		$ 244
2016 Plan | Restricted stock | Award Date of March 8, 2017
Stock-Based Compensation
Awards, other than options, granted (in shares)	5,212
Share price (in dollars per share)	$ 13.68
Annual vesting (as a percent)	33.33%
Vesting period	3 years
2016 Plan | Restricted Stock, Initial grant | Award Date of September 28, 2016
Stock-Based Compensation
Annual vesting (as a percent)		33.33%
Vesting period		3 years
2016 Plan | Restricted Stock, Annual grant | Maximum | Award Date of September 28, 2016
Stock-Based Compensation
Vesting period		1 year

Stock-Based Compensation - Opti

Stock-Based Compensation - Options Valuation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Stock-Based Compensation
Stock-based compensation expense (in dollars)	$ 3,821	$ 127
Stock options
Stock-Based Compensation
Stock-based compensation expense (in dollars)	$ 690	$ 127
Employee stock options
Valuation assumptions:
Expected volatility (as a percent)	61.00%	59.00%
Expected life	6 years 11 days	6 years 29 days
Risk-free interest rate (as a percent)	2.24%	1.49%
Weighted average grant-date fair value (in dollars per share)	$ 7.89	$ 7.29

Stock-Based Compensation - Op61

Stock-Based Compensation - Options Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2016USD ($)shares
Additional disclosures
Intrinsic value of options exercised (in dollars) | $	$ 8,660	$ 832
Proceeds from stock options exercised (in dollars) | $	$ 50
Shares delivered as payment for exercise	329,587	7,930
Stock options exercised in cashless transaction	776,422	71,150
Gross exercise value | $	$ 2,816	$ 104
2016 Plan
Number of shares
Outstanding at beginning of period (in shares)	3,059,690
Granted (in shares)	961,075
Exercised (in shares)	(793,225)
Forfeited (in shares)	(7,678)
Outstanding at end of the period (in shares)	3,219,862
Options vested and expected to vest at end of the period (in shares)	3,219,862
Exercisable at end of period (in shares)	1,535,362
Weighted average exercise price
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 5.14
Granted (in dollars per share) | $ / shares	14.03
Exercised (in dollars per share) | $ / shares	3.61
Forfeited (in dollars per share) | $ / shares	11.31
Outstanding at end of period (in dollars per share) | $ / shares	8.16
Options vested and expected to vest at end of period (in dollars per share) | $ / shares	8.16
Exercisable at end of period (in dollars per share) | $ / shares	$ 3.02
Weighted average remaining contractual term
Outstanding	7 years 8 months 12 days
Options vested and expected to vest at of the period	7 years 8 months 12 days
Exercisable	5 years 7 months 6 days
Aggregate intrinsic value
Outstanding (in dollars) | $	$ 18,186
Options vested and expected to vest at end of period (in dollars) | $	18,186
Exercisable (in dollars) | $	16,065
Stock options | 2016 Plan
Additional disclosures
Total unrecognized compensation cost (in dollars) | $	$ 11,096
Weighted average period expected to be recognized	3 years 1 month 6 days
Non-employee options | 2016 Plan
Number of shares
Outstanding at end of the period (in shares)	188,893
Additional disclosures
Unvested options (in shares)	1,241

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Stock-based compensation expense
Stock-based compensation expense (in dollars)	$ 3,821	$ 127
Cost of revenue - product
Stock-based compensation expense
Stock-based compensation expense (in dollars)	95	29
Cost of revenue - service
Stock-based compensation expense
Stock-based compensation expense (in dollars)	43	7
Research and development
Stock-based compensation expense
Stock-based compensation expense (in dollars)	104	11
Selling and marketing
Stock-based compensation expense
Stock-based compensation expense (in dollars)	117	22
General and administrative
Stock-based compensation expense
Stock-based compensation expense (in dollars)	$ 3,462	$ 58

Fair Value Measurements - Liabi

Fair Value Measurements - Liabilities (Details) - Recurring - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Fair Value Measurements
Acquisition-related contingent consideration - short-term	$ 1,531	$ 1,493
Acquisition-related contingent consideration - long-term		1,515
Liabilities	1,531	3,008
Level 3
Fair Value Measurements
Acquisition-related contingent consideration - short-term	1,531	1,493
Acquisition-related contingent consideration - long-term		1,515
Liabilities	$ 1,531	$ 3,008

Fair Value Measurements - Conti

Fair Value Measurements - Contingent consideration Rollforward (Details) - Acquisition related contingent consideration $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Change in fair value using significant unobservable inputs (Level 3):
Balance at beginning of period	$ 3,008
Fair value of cash consideration paid	(1,498)
Adjustments to fair value measurement	21
Balance at end of period	$ 1,531

Commitments and Contingencies -

Commitments and Contingencies - Letter of Credit (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2015
2015 Revolving Line
Letter of Credit
Letter of credit liability	$ 500	$ 500	$ 500

Retirement Plan (Details)

Retirement Plan (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Retirement Plan
Contributions by employer	$ 136	$ 0

Related-Party Transactions (Det

Related-Party Transactions (Details) - Stockholder - 2015 Demand Promissory Note - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2016
Related-Party Transactions
Notes payable to related parties		$ 250
Interest rate (as a percent)		6.00%
Interest Expense, Related Party	$ 4

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event $ in Thousands	Apr. 25, 2017USD ($)
Employment Agreement
Subsequent Event
Initial term of agreement	3 years
Common Stock
Subsequent Event
Number of shares authorized to be repurchased	$ 5,000